The SLC7A5 antibody is a research tool designed to detect and study the solute carrier family 7 member 5 (SLC7A5), a transmembrane protein also known as LAT1 (L-type amino acid transporter 1). SLC7A5 forms a heterodimer with SLC3A2 (CD98hc) to function as a bidirectional transporter of large neutral amino acids, such as leucine, across cell membranes. It plays a critical role in nutrient uptake, cellular metabolism, and mTOR signaling, making it essential for cell growth and proliferation.
SLC7A5 is highly expressed in rapidly dividing cells, including cancer cells and activated immune cells, where it supports elevated metabolic demands. Its overexpression in tumors correlates with poor prognosis, highlighting its potential as a therapeutic target. The antibody is widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate SLC7A5 expression patterns, subcellular localization, and regulatory mechanisms in both physiological and pathological contexts.
In cancer research, SLC7A5 antibodies help elucidate its role in tumor progression, drug resistance, and immune microenvironment modulation. Additionally, studies explore its involvement in neurological disorders and autoimmune diseases. Validated antibodies are crucial for distinguishing SLC7A5 from related transporters and ensuring specificity in experimental models, aiding the development of targeted therapies.